{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:36:01Z","timestamp":1648650961416},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12325-020-01402-1","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T17:20:40Z","timestamp":1595006440000},"page":"3878-3900","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects"],"prefix":"10.1007","volume":"37","author":[{"given":"Masaomi","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Cerneus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"van der Heide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stoelzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"1402_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2174\/156800705774933050","volume":"4","author":"RA Puffenbarger","year":"2005","unstructured":"Puffenbarger RA. Molecular biology of the enzymes that degrade endocannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4:625\u201331.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"11","key":"1402_CR2","first-page":"1247","volume":"25","author":"A Lodola","year":"2015","unstructured":"Lodola A, Castelli R, Mor M, Rivara S. Fatty acid amide hydrolase inhibitors: a patent review (2009\u20132014). Expert Opin Ther Pat. 2015;25(11):1247\u201366.","journal-title":"Expert Opin Ther Pat"},{"key":"1402_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/3-540-26573-2_12","volume":"168","author":"CW Vaughan","year":"2005","unstructured":"Vaughan CW, Christie MJ. Retrograde signaling by endocannabinoids. Handb Exp Pharmacol. 2005;168:367\u201383.","journal-title":"Handb Exp Pharmacol"},{"key":"1402_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0165-6147(00)01805-8","volume":"22","author":"E Schlicker","year":"2001","unstructured":"Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:565\u201372.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1402_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4):588\u2013631.","journal-title":"Pharmacol Rev"},{"key":"1402_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1464-410X.2010.09583.x","volume":"108","author":"FV Merriam","year":"2011","unstructured":"Merriam FV, Wang ZY, Hillard CJ, et al. Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. BJU Int. 2011;108:1145\u20139.","journal-title":"BJU Int"},{"issue":"2\u20133","key":"1402_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1054\/plef.2001.0341","volume":"66","author":"RG Pertwee","year":"2002","unstructured":"Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids. 2002;66(2\u20133):101\u201321.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"10","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/nn.2632","volume":"13","author":"JR Clapper","year":"2010","unstructured":"Clapper JR, Moreno-Sanz G, Russo R, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010;13(10):1265\u201370.","journal-title":"Nat Neurosci"},{"issue":"51","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"13318","DOI":"10.1523\/JNEUROSCI.3326-06.2006","volume":"26","author":"MD Jhaveri","year":"2006","unstructured":"Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci. 2006;26(51):13318\u201327.","journal-title":"J Neurosci"},{"key":"1402_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","volume":"11","author":"C Muller","year":"2019","unstructured":"Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487.","journal-title":"Front Mol Neurosci"},{"key":"1402_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/MJT.0b013e3180a5e581","volume":"14","author":"BH McCarberg","year":"2007","unstructured":"McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther. 2007;14:475\u201383.","journal-title":"Am J Ther"},{"issue":"1","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ab.2009.08.005","volume":"395","author":"A Ozalp","year":"2009","unstructured":"Ozalp A, Barroso B. Simultaneous quantitative analysis of N-acylethanolamides in clinical samples. Anal Biochem. 2009;395(1):68\u2013766.","journal-title":"Anal Biochem"},{"key":"1402_CR13","doi-asserted-by":"publisher","first-page":"754.e1","DOI":"10.1016\/j.ahj.2005.11.006","volume":"151","author":"DA Gorelick","year":"2006","unstructured":"Gorelick DA, Heishman SJ, Preston KL, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J. 2006;151:754.e1\u2013.e5.","journal-title":"Am Heart J"},{"key":"1402_CR14","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1097\/j.pain.0000000000001278","volume":"159","author":"Z Hong","year":"2018","unstructured":"Hong Z, Dominique ML, Haley AC, et al. A peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain. 2018;159:1814\u201323.","journal-title":"Pain"},{"key":"1402_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2017.02.029","volume":"103","author":"FME Wagenlehner","year":"2017","unstructured":"Wagenlehner FME, van Till JWO, Houbiers JGA, et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis\/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology. 2017;103:191\u20137.","journal-title":"Urology"},{"key":"1402_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.clinthera.2020.03.021","volume":"42","author":"M Takizawa","year":"2020","unstructured":"Takizawa M, Hatta T, Iitsuka H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of ASP3652, a reversible fatty acid amide hydrolase inhibitor, in a randomized, double-blind, placebo-controlled, single and multiple oral dose phase I study in healthy non-elderly male and elderly male and female Japanese subjects. Clin Ther. 2020;42:906\u201323.","journal-title":"Clin Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01402-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:11:40Z","timestamp":1626480700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01402-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01402-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}